Twohrg-1-specific siRNAs, siHRG1 and siHRG2, effectively suppress expression of HRG-1 in HeLa cells compared with control siRNA (Fig

Twohrg-1-specific siRNAs, siHRG1 and siHRG2, effectively suppress expression of HRG-1 in HeLa cells compared with control siRNA (Fig. is essential for endosomal acidification, heme binding, and receptor trafficking in mammalian cells. Thus, HRG-1 may facilitate tumor growth and cancer progression. Keywords:Diseases/Cancer, Diseases/Cancer/Transformation, Hormones/Growth Factors, Hormones/Insulin, Metabolism/Glucose, Signal Transduction/Protein Kinases, Insulin-Like Growth Factor I, Vacuolar ATPase PF 670462 == Introduction == Cancer cell invasiveness is associated with increased expression of components of the endocytic trafficking machinery (1,2), and altered trafficking of growth factor receptors and integrins may have a profound effect on tumor growth and invasive potential (3,4). Cancer cells are also highly dependent on a continuous supply of nutrients and micronutrients. These are acquired through transporters Rabbit polyclonal to LEPREL1 that may be either channels or receptors that deliver their cargo via endocytosis (46). The expression levels and trafficking of nutrient transporters are tightly regulated by growth factors, especially through activity of the insulin/IGF-I3-activated PI3K/mammalian target of rapamycin signaling pathway (7). Both overexpression of nutrient transporters and decreased degradation in lysosomes have been linked to cellular transformation (7,8). An increasingly acidic lumenal pH gradient from early to late endosomes is required for receptor trafficking and is maintained by the V-ATPase proton pump acting in concert with other pH regulatory channels (9,10). The V-ATPase consists of two multisubunit domains. The V1domain has eight subunits (AH), is located on the cytoplasmic side of membranes, and hydrolyzes ATP. PF 670462 The V0domain has six subunits (a, d, e, c, c, and c), is embedded in membranes, and translocates protons. Activity of the complex is regulated in at least three ways as follows: by reversible domain assembly, which is dependent on glucose and PI3K signaling; by the RAVE regulatory protein complex in yeast; and by targeting of subunits to specific membranes (1013). In mammals, further regulation may be attributed to subunit isoforms that target V-ATPase to specific tissues or organelles (9,10). The V-ATPase has been detected at the plasma membrane of cancer cells (14,15), which is thought to favor invasiveness, although the c subunit from the V0domain PF 670462 has been associated with promoting cellular transformation (16). Very little is known about the regulation of V-ATPase function in epithelial cancer cells. Nonetheless, it is reasonable to propose that it may be influenced by the insulin/IGF-I/PI3K signaling pathway, which has increased activity in PF 670462 many cancers. PI3K has been shown to be essential for V-ATPase assembly in renal PF 670462 epithelial cells (12). In an effort to identify IGF-I-regulated proteins that are important for cancer progression, we isolated a series of genes that are differentially expressed in nontransformed cells (R, derived from the IGF-IR knock-out mouse) and highly transformed cells (R+and Rcells that overexpress the IGF-IR) (1719). Among these was a gene encoding an endosomal protein that we found to associate with the endosomal V-ATPase and to regulate V-ATPase activity in endosomes. As this study was completed, the same gene was identified to encode a heme-binding protein necessary for heme homeostasis inCaenorhabditis elegansand for erythropoiesis and development in zebrafish (20). Heme transport into and within cells may involve endocytosis and trafficking of heme transporters/receptors (2123). Overall, our data indicate that HRG-1 is the first known heme-binding protein that regulates function of the V-ATPase in endosome acidification and trafficking of receptors essential for cell metabolism. == MATERIALS AND METHODS == == == == == == General Reagents and Antibodies == IGF-I was from PeproTech Inc. (Rocky Hill, NJ), Concanamycin A, bafilomycin A, nocodazole, propidium iodide, goat serum, crystal violet, leupeptin, E-64, FITC-transferrin and FITC-dextran 40 kDa (FD40), DMEM, glucose-free DMEM, sodium azide, 2-deoxy-d-glucose, nigericin, NaCl and all other salts and reagents were from Sigma unless otherwise stated. LY294002, rapamycin, and PD89059 were from Calbiochem. Alexa-488 transferrin, LysoTracker Red, and LysoSensor Green were from Molecular Probes (Eugene, OR). Antibodies used were as follows: anti-EEA1 (BD Transduction Laboratories); anti-transferrin receptor and anti-Rab11 antibody (Zymed Laboratories Inc.); anti–actin and Rab7 (Sigma); anti-LAMP1 and anti-HA (clone 16B12) (Covance); anti-His (Qiagen, UK); anti-c subunit (Chemicon); and anti-A1 subunit (Santa Cruz Biotechnology). Generation of mouse monoclonal V-ATPase anti-A subunit antibody was described previously (24). == Cloning of Human HRG-1 cDNA == cDNA encoding the humanHRG-1gene sequence was obtained from the I.M.A.G.E. Consortium. The open reading frame (nucleotides 98538) was amplified by PCR using primers to incorporate XhoI restriction sites at the 5 and 3 ends and ligated into the pcDNA3-HA.